A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2024
The goal of this clinical trial is to learn if the investigational drug CAL101 can help prevent further decline in lung function in adults with Idiopathic Pulmonary Fibrosis. Researchers will compare CAL101 with placebo to compare change from baseline in forced vital capacity (FVC). Participants will be randomly assigned to a study group that will receive an IV infusion of either the study medication or placebo about once a month for 6 months.
Epistemonikos ID: cb011dd0fdd945de1cdf10cc56f98cd3bacd2777
First added on: Jan 01, 2025